$AMRN
AMARIN CORP PLC\UK Stock $amrn

$amrn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000095017022007188 Filed on May 04, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$94.63M	$142.2M
YoY Change	-33.44%	-8.27%
Cost Of Revenue	$22.24M	$28.33M
YoY Change	-21.49%	-18.62%
Gross Profit	$72.39M	$113.8M
YoY Change	-36.41%	-5.28%
Gross Profit Margin	76.5%	80.08%
Selling, General & Admin	$90.65M	$105.8M
YoY Change	-14.32%	-21.01%
% of Gross Profit	125.22%	92.93%
Research & Development	$10.05M	$9.377M
YoY Change	7.19%	-8.77%
% of Gross Profit	13.88%	8.24%
Depreciation & Amortization	$780.0K	$511.0K
YoY Change	52.64%	0.99%
% of Gross Profit	1.08%	0.45%
Operating Expenses	$100.7M	$115.2M
YoY Change	-12.57%	-20.14%
Operating Profit	-$28.31M	-$1.331M
YoY Change	2026.75%	-94.46%
Interest Expense	$203.0K	$471.0K
YoY Change	-56.9%	-61.01%
% of Operating Profit
Other Income/Expense, Net	-$246.0K	-$142.0K
YoY Change	73.24%	56.04%
Pretax Income	-$28.35M	-$1.002M
YoY Change	2729.34%	-95.63%
Income Tax	$3.213M	$624.0K
% Of Pretax Income
Net Earnings	-$31.56M	-$1.626M
YoY Change	1841.14%	-92.09%
Net Earnings / Revenue	-33.35%	-1.14%
Basic Earnings Per Share	-$0.08	$0.00
Diluted Earnings Per Share	-$0.08	$0.00
COMMON SHARES
Basic Shares Outstanding	397.8M	394.6M
Diluted Shares Outstanding	397.8M	394.6M

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$362.6M	$514.7M
YoY Change	-29.56%	-5.07%
Cash & Equivalents	$219.2M	$291.0M
Short-Term Investments	$143.4M	$223.7M
Other Short-Term Assets	$32.01M	$33.61M
YoY Change	-4.77%	36.25%
Inventory	$267.8M	$230.9M
Prepaid Expenses
Receivables	$110.2M	$151.3M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$772.6M	$930.5M
YoY Change	-16.97%	13.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.281M	$9.820M
YoY Change	-86.96%	-9.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$26.70M	$24.00M
YoY Change	11.24%	-70.55%
Other Assets	$456.0K	$456.0K
YoY Change	0.0%	-57.54%
Total Long-Term Assets	$201.1M	$59.80M
YoY Change	236.29%	-44.82%
TOTAL ASSETS
Total Short-Term Assets	$772.6M	$930.5M
Total Long-Term Assets	$201.1M	$59.80M
Total Assets	$973.7M	$990.3M
YoY Change	-1.68%	6.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$90.75M	$94.26M
YoY Change	-3.72%	-4.14%
Accrued Expenses	$207.6M	$228.7M
YoY Change	-9.23%	33.97%
Deferred Revenue	$2.198M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$300.6M	$325.8M
YoY Change	-7.73%	4.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.490M	$29.87M
YoY Change	-74.93%	1.04%
Total Long-Term Liabilities	$7.490M	$29.87M
YoY Change	-74.93%	1.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$300.6M	$325.8M
Total Long-Term Liabilities	$7.490M	$29.87M
Total Liabilities	$332.6M	$355.6M
YoY Change	-6.48%	4.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.453B
YoY Change
Common Stock	$294.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$61.26M
YoY Change
Treasury Stock Shares	$7.648M	$6.891M
Shareholders Equity	$641.1M	$634.6M
YoY Change
Total Liabilities & Shareholders Equity	$973.7M	$990.3M
YoY Change	-1.67%	6.98%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$31.56M	-$1.626M
YoY Change	1841.14%	-92.09%
Depreciation, Depletion And Amortization	$780.0K	$511.0K
YoY Change	52.64%	0.99%
Cash From Operating Activities	-$98.85M	-$18.70M
YoY Change	428.48%	-552.12%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$99.05M	$127.9M
YoY Change	-22.58%	-143.58%
Cash From Investing Activities	$99.05M	$127.9M
YoY Change	-22.58%	-143.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-505.0K	-5.193M
YoY Change	-90.28%	-79.91%
NET CHANGE
Cash From Operating Activities	-98.85M	-18.70M
Cash From Investing Activities	99.05M	127.9M
Cash From Financing Activities	-505.0K	-5.193M
Net Change In Cash	-303.0K	104.0M
YoY Change	-100.29%	-132.97%
FREE CASH FLOW
Cash From Operating Activities	-$98.85M	-$18.70M
Capital Expenditures		$0.00
Free Cash Flow		-$18.70M
YoY Change		-581.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.amarincorp.com/20220331#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	AMARIN CORP PLC\UK
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000897448
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8689000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7660000
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities
CY2021	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	000-21392
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	77 Sir John Rogerson’s Quay
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Block C
CY2022Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	Grand Canal Docklands
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2
CY2022Q1	dei	Entity Address Country EntityAddressCountry	IE
CY2022Q1	dei	City Area Code CityAreaCode	353 (0) 1
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	6699 020
CY2022Q1	dei	Security12b Title Security12bTitle	American Depositary Shares (ADS(s)), each ADSrepresenting the right to receive one (1) Ordinary Share ofAmarin Corporation plc
CY2022Q1	dei	Trading Symbol TradingSymbol	AMRN
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	219151000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	219454000
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3918000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3918000
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	143406000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	234674000
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110234000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	163653000
CY2022Q1	us-gaap	Inventory Net InventoryNet	267818000
CY2021Q4	us-gaap	Inventory Net InventoryNet	234676000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28092000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22352000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	772619000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	878727000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1281000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1425000
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	26701000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7648000
CY2022Q1	us-gaap	Liabilities Liabilities	332600000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	34996000
CY2022Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	141052000
CY2021Q4	us-gaap	Liabilities Liabilities	400966000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	121254000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	404588758
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	456000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	456000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22911000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23547000
CY2022Q1	us-gaap	Assets Assets	973709000
CY2021Q4	us-gaap	Assets Assets	1068065000
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	90753000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	114922000
CY2022Q1	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	207622000
CY2021Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	253111000
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2198000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2649000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	300573000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	370682000
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	14139000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	14060000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10398000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8576000
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7490000
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	396940908
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	404084775
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	396598008
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	294364000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	294027000
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1861017000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1855246000
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	7647850
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7486767
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	61261000
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	60726000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1453011000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1421448000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	641109000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	667099000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	973709000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1068065000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94630000
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142170000
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22239000
CY2022Q1	us-gaap	Gross Profit GrossProfit	72391000
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-31563000
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28326000
CY2021Q1	us-gaap	Gross Profit GrossProfit	113844000
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	90647000
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	105798000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10051000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9377000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	100698000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	115175000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28307000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1331000
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	203000
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	471000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-246000
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28350000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1002000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3213000
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	624000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31563000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1626000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	397805000
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	394638000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	397805000
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	394638000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	667099000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-535000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6078000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31563000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	641109000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627505000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2059000
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-7252000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13925000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1626000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	634611000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-1626000
CY2022Q1	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	144000
CY2021Q1	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	150000
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-374000
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-649000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6078000
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	113220000
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13925000
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	636000
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	127925000
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	361000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-53419000
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3299000
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	52940000
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	42028000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5740000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1251000
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	24000
CY2022Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-140000
CY2021Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-118000
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-372000
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-662000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-69658000
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	6479000
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	635000
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-596000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98847000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18704000
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	14171000
CY2022Q1	amrn	Disposal Purchase Of Furniture Fixtures And Equipment DisposalPurchaseOfFurnitureFixturesAndEquipment	0
CY2021Q1	amrn	Disposal Purchase Of Furniture Fixtures And Equipment DisposalPurchaseOfFurnitureFixturesAndEquipment	4000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	99049000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	127929000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2059000
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	535000
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7252000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-505000
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5193000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-303000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	104032000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	223372000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	190879000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	223069000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	294911000
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51000
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5000
CY2022Q1	amrn	Initial Recognition Of Operating Lease Right Of Use Asset InitialRecognitionOfOperatingLeaseRightOfUseAsset	1036000
CY2021Q1	amrn	Initial Recognition Of Operating Lease Right Of Use Asset InitialRecognitionOfOperatingLeaseRightOfUseAsset	0
CY2022Q1	amrn	Non Cash Or Part Non Cash Milestone Payment NonCashOrPartNonCashMilestonePayment	0
CY2021Q1	amrn	Non Cash Or Part Non Cash Milestone Payment NonCashOrPartNonCashMilestonePayment	12000000
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q1	us-gaap	Assets Assets	973700000
CY2022Q1	amrn	Cash And Liquid Short Term And Long Term Investments CashAndLiquidShortTermAndLongTermInvestments	389300000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	772600000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	219200000
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	143400000
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110200000
CY2022Q1	us-gaap	Inventory Net InventoryNet	267800000
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	26700000
CY2022Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	141100000
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2022Q1	amrn	Accounts Receivable Credit Period AccountsReceivableCreditPeriod	P30D
CY2022Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	217821000
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	262948000
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110234000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	163653000
CY2022Q1	amrn	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-31563000
CY2021Q1	amrn	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-1626000
CY2022Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	397805000
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	394638000
CY2022Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents, short-term and long-term investments, and accounts receivable. The Company maintains substantially all of its cash and cash equivalents and short-term and long-term investments, in financial institutions believed to be of high-credit quality.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A significant portion of the Company’s sales are to wholesalers in the pharmaceutical industry. The Company monitors the creditworthiness of customers to whom it grants credit terms and has not experienced any credit losses. The Company does not require collateral or any other security to support credit sales. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> customers individually accounted for 10% or more of the Company’s gross product sales, Customers A, B, and C accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of gross product sales for the three months ended March 31, 2022, and represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of the gross accounts receivable balance as of March 31, 2022. Customers A, B, and C accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of gross product sales for the three months ended March 31, 2021 and represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of the gross accounts receivable balance as of March 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company has not experienced any significant write-offs of its accounts receivable. All customer accounts are actively managed and no losses in excess of amounts reserved are currently expected; however, the Company is monitoring the potential negative impact of COVID-19 on the Company’s customers’ ability to meet their financial obligations.</span></p>
CY2022Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P24M
CY2022Q1	amrn	Held To Maturity Securities Continuous Unrealized Gain Loss On Position Fair Value HeldToMaturitySecuritiesContinuousUnrealizedGainLossOnPositionFairValue	-900000
CY2021Q1	amrn	Held To Maturity Securities Continuous Unrealized Gain Loss On Position Fair Value HeldToMaturitySecuritiesContinuousUnrealizedGainLossOnPositionFairValue	200000
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q1	amrn	Number Of Sales Representatives NumberOfSalesRepresentatives	300
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	0
CY2021Q1	us-gaap	Restructuring Charges RestructuringCharges	0
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	1186000
CY2022Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	948000
CY2022Q1	us-gaap	Restructuring Reserve RestructuringReserve	238000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9Y
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32081000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32081000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9170000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8534000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22911000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23547000
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	123318000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	107695000
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	56217000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	41965000
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	229335000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	206270000
CY2022Q1	amrn	Inventory Current And Non Current InventoryCurrentAndNonCurrent	408870000
CY2021Q4	amrn	Inventory Current And Non Current InventoryCurrentAndNonCurrent	355930000
CY2022Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	141100000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	121300000
CY2022Q1	us-gaap	Purchase Obligation PurchaseObligation	49300000
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10602
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	783320
CY2022Q1	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	30000
CY2021Q1	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	2059000
CY2021Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	280693000
CY2022Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	179774000
CY2022Q1	amrn	Provision Related To Prior Period Sales ProvisionRelatedToPriorPeriodSales	301000
CY2022Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	76832000
CY2022Q1	amrn	Credits Payments Made For Prior Period Sales CreditsPaymentsMadeForPriorPeriodSales	139615000
CY2022Q1	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	243719000
CY2020Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	190827000
CY2021Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	191325000
CY2021Q1	amrn	Provision Related To Prior Period Sales ProvisionRelatedToPriorPeriodSales	854000
CY2021Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	29525000
CY2021Q1	amrn	Credits Payments Made For Prior Period Sales CreditsPaymentsMadeForPriorPeriodSales	121126000
CY2021Q1	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	230647000
CY2022Q1	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	true
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16709000
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	372000
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16337000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18632000
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	662000
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17970000
CY2022Q1	amrn	Contract With Customer Liability Revenue Recognized Excluding Performance Obligation Satisfied In Previous Period ContractWithCustomerLiabilityRevenueRecognizedExcludingPerformanceObligationSatisfiedInPreviousPeriod	372000
CY2021Q1	amrn	Contract With Customer Liability Revenue Recognized Excluding Performance Obligation Satisfied In Previous Period ContractWithCustomerLiabilityRevenueRecognizedExcludingPerformanceObligationSatisfiedInPreviousPeriod	662000
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.115
CY2022Q1	amrn	Operating Lease Change In Weighted Average Discount Rate Percent OperatingLeaseChangeInWeightedAverageDiscountRatePercent	0.01
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11300000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10300000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8700000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7700000
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1626000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2182000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2138000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2095000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2129000
CY2022Q1	amrn	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	7213000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17383000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6048000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	937000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10398000

Files In Submission

Name	View Source	Status
0000950170-22-007188-index-headers.html	Edgar Link	pending
0000950170-22-007188-index.html	Edgar Link	pending
0000950170-22-007188.txt	Edgar Link	pending
0000950170-22-007188-xbrl.zip	Edgar Link	pending
amrn-20220331.htm	Edgar Link	pending
amrn-20220331.xsd	Edgar Link	pending
amrn-20220331_cal.xml	Edgar Link	unprocessable
amrn-20220331_def.xml	Edgar Link	unprocessable
amrn-20220331_htm.xml	Edgar Link	completed
amrn-20220331_lab.xml	Edgar Link	unprocessable
amrn-20220331_pre.xml	Edgar Link	unprocessable
amrn-ex31_1.htm	Edgar Link	pending
amrn-ex31_2.htm	Edgar Link	pending
amrn-ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img151385700_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRN
AMARIN CORP PLC\UK Stock $amrn

2022 Q1 Form 10-Q Financial Statement

#000095017022007188 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN AMARIN CORP PLC\UK Stock $amrn

2022 Q1 Form 10-Q Financial Statement

#000095017022007188 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN
AMARIN CORP PLC\UK Stock $amrn